pharmaphorum

FEBRUARY 23, 2022

Code Bio’s 3DNA vectors are based on pieces of synthetic DNA linked together to form a scaffold that can carry a larger gene sequence than viral vectors, and according to the biotech don’t trigger an immune response which might cause side effects or limit the potential for re-dosing.

Gene Therapy 100

Gene Therapy Gene Gene Sequencing Immune Response 100

Drug Discovery World

FEBRUARY 5, 2024

Brian Gladsden, CEO, Mosaic Therapeutics “The industry has already made tremendous strides in targeted drug discovery in oncology, particularly as the industry moves further away from simply looking at tumour histology and relying more on cancer gene sequencing.

Research 116

Research Drug Delivery Systems Gene Sequencing Trials 116

pharmaphorum

MAY 18, 2021

.” The interim phase 2 results show that two doses of the plant-derived jab stimulated neutralising antibody levels that are around 10 times higher than those in a panel of sera from patients recovering from COVID-19, with a similar response seen in adults and the elderly.

Immune Response 62

Immune Response Vaccination Vaccine Gene Sequencing 62

pharmaphorum

FEBRUARY 22, 2021

That therapy uses an adeno-associated virus (AAV) as a vector rather than a lentivirus, a vector type that features in approved gene therapies such as Roche’s Luxturna and Novartis’ Zolgensma. million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52